Uterine Corpus Cancer Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Uterine Corpus Cancer. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Uterine Corpus Cancer receives a directional score of 62/100, combining unmet need (76/100), competitive intensity (86/100) and market attractiveness (79/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A malignant neoplasm arising from the uterine corpus. This category includes endometrial carcinoma and carcinosarcoma.

The reproducible record is Patsnap disease ID 58865ba372754a6a8d39735887b6cb69. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Uterine corpus cancer is the sixth most commonly diag- nosed cancer in women, with 417,000 new cases and 97,000 deaths in 2020 (Table 1). Incidence rates vary 10-fold across world regions with the highest rates seen in Northern America, Europe, Micronesia/Polynesia, and Australia/New Zealand and the lowest incidence rates in most African regions and South Central Asia (Fig. 21). Less regional variation was seen for mortality rates, with the highest in Eastern Europe, Micronesia/Polynesia, the Caribbean, and Northern America. Incidence rates have increased or stabi- lized since the late 1990s in many countries across regions, with South Africa and several countries in Asia showing the fastest increase.232 Birth cohort effects were most evident in Japan, the Philippines, Belarus, Singapore, India, Belarus, Lithuania, Costa Rica, and New Zealand,232 possibly in part reflecting increases in the prevalence of risk factors (eg, excess body weight, physical inactivity) in subsequently younger generations. There are several cancers that, although not featured among the top 10 cancers, are major cancers within certain regions or specific countries. With approximately 34,000 new cases and 15,000 deaths (Table 1), Kaposi sarcoma is a relatively rare cancer worldwide but is endemic in several countries in Southern and Eastern Africa (Fig. 22) and is the leading cause of both cancer incidence and mor- tality among men in 2020 in Mozambique and Uganda (Figs. 5A and 6A); rates are the highest worldwide in Mozambique for men and in Zambia for women (Fig. 22). Cancers of the lip and oral ca

Review source

Epidemiology evidence 2: Cancer treatment and survivorship statistics, 2025

Uterine corpus (endometrium) As of January 1, 2025, it is estimated that 945,540 women are living in the United States with a previous diagnosis of uterine corpus cancer, and an additional 69,120 new cases are expected to be diagnosed in 2025.16 By January 1, 2035, the prevalence is projected to reach nearly 1.2 million (Figure 2). Cancer of the uterine corpus is often referred to as endometrial cancer because more than 90% of cases arise in the endometrium.20 It is the second most prevalent cancer among women after breast cancer and has a median age at diagnosis of 63 years.22 Treatment and survival Among patients with early stage (stage I) uterine corpus cancer, 69% undergo hysterectomy and bilateral salpingo‐oophorectomy without chemotherapy or radiation (Figure 16), with ovarian preservation possible for a select group of premenopausal women who have early disease (i.e., stage IA).201 Most patients with stage II disease (64%) undergo surgery alone or with radiation, whereas the majority of patients with stage III disease (71%) undergo surgery and receive chemotherapy with or without radiation (Figure 16). Black women are more likely to receive chemotherapy after surgery, with or without radiation, for both stage I and stage II disease (Figure 16), likely reflecting the higher proportion of nonendometrioid disease, which is generally more aggressive than endometrioid disease.202 When stratified by disease subtype, receipt of guideline‐concordant therapy in hospital‐based studies was lower among Black women than among White women for endometrioid subtypes203 but was simil

Review source

Epidemiology evidence 3: Cancer statistics for African American and Black people, 2025 Cancer statistics for African American and Black people,2025

are less likely to receive recommended treatment (i.e., surgery, ra- diation therapy) for cervical cancer.179,180 Uterine corpus An estimated 9380 new cases and 3060 deaths from uterine corpus cancer will occur among Black women in 2025. Cancer of the uterine corpus is often referred to as endometrial cancer because >90% of cases occur in the endometrium.15 The uterine cancer incidence rate in Black women (29.7 per 100,0000) is similar to that in White women (28.1 per 100,000) without correction for hysterectomy prevalence, but higher after accounting for hyster- ectomy,29 although this disparity varies by state and nativity within the Black population in the United States. A population‐based study reported that hysterectomy‐corrected incidence rates for type 2 endometrial cancer (i.e., subtypes with poorer prognoses) were highest among US‐born Black women (24.4 per 100,000) followed by Caribbean‐born Black women (18.2 per 100,000).181 Endometrial cancer incidence rates were approximately 50% lower in Black women than in White women in the early 1970s but have recently converged, largely because of steeper increases in Black women that also began earlier than in White women. Some of the increase may be related to the obesity epidemic (Figure 7) because 53% of uterine corpus cancers are attributable to excess body weight.95 However, a recent study reported that non- endometrioid subtypes, which are less strongly associated with obesity than endometrioid carcinoma, are driving the trend.29 From 2017 to 2021, incidence rates increased by about 2% per year in Black women but ap

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Uterine Corpus Cancer, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Uterine Corpus Cancer thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor is PTH1R, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 131 registered studies.

• NCT07671937 — INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study (INSPIRE); Not yet recruiting; Not Applicable; sponsor The University of Alabama at Birmingham, University of Oklahoma, University of California, Los Angeles; enrollment 2748.
• DRKS00040267 — FertiBAY - Fertility-Preserving Surgery in Patients with Early-Stage Endometrial, Cervical, and Ovarian Cancer, as well as Atypical Endometrial Hyperplasia and Ovarian Borderline Tumors; Pending; Not Applicable; sponsor not stated; enrollment 500.
• DRKS00040032 — Prospective Assessment of Quality of Life During Radiotherapy for the Treatment of Gynecological tumors; Recruiting; Not Applicable; sponsor not stated; enrollment 175.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate PTH1R relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Uterine Corpus Cancer merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Uterine Corpus Cancer is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.